Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Algert Global LLC

Algert Global LLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 17,720 shares of the company's stock after selling 97,959 shares during the quarter. Algert Global LLC's holdings in Protagonist Therapeutics were worth $684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its position in Protagonist Therapeutics by 8.2% during the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock worth $72,432,000 after acquiring an additional 142,376 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Protagonist Therapeutics by 6.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock valued at $53,758,000 after buying an additional 83,185 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Protagonist Therapeutics by 3,025.4% in the 4th quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock valued at $36,287,000 after buying an additional 909,998 shares during the period. American Century Companies Inc. lifted its holdings in shares of Protagonist Therapeutics by 61.5% in the 4th quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock valued at $35,832,000 after buying an additional 353,511 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Protagonist Therapeutics by 13.1% in the 4th quarter. Invesco Ltd. now owns 738,952 shares of the company's stock valued at $28,524,000 after buying an additional 85,800 shares during the period. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Trading Down 2.0%

NASDAQ:PTGX opened at $43.04 on Monday. Protagonist Therapeutics, Inc. has a 12 month low of $27.00 and a 12 month high of $60.60. The stock has a 50 day moving average of $46.95 and a two-hundred day moving average of $42.67. The firm has a market cap of $2.67 billion, a P/E ratio of 16.18 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price objective on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, February 24th. JMP Securities reissued a "market outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Truist Financial lifted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. Finally, JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Protagonist Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $65.44.

Insider Activity

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares in the company, valued at $20,627,126.80. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares of the company's stock, valued at $712,302.50. This trade represents a 23.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,532 shares of company stock worth $3,665,786 over the last ninety days. Corporate insiders own 5.40% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.